Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Serina Therapeutics (SER) over the last 8 years, with Q2 2025 value amounting to 4280.77%.

  • Serina Therapeutics' EBIT Margin rose 32996200.0% to 4280.77% in Q2 2025 from the same period last year, while for Sep 2025 it was 20141.38%, marking a year-over-year decrease of 197847700.0%. This contributed to the annual value of 30442.86% for FY2024, which is 303436200.0% down from last year.
  • Per Serina Therapeutics' latest filing, its EBIT Margin stood at 4280.77% for Q2 2025, which was up 32996200.0% from 39635.71% recorded in Q4 2024.
  • Serina Therapeutics' 5-year EBIT Margin high stood at 39635.71% for Q4 2024, and its period low was 46420.0% during Q1 2024.
  • Over the past 5 years, Serina Therapeutics' median EBIT Margin value was 6975.0% (recorded in 2021), while the average stood at 11522.48%.
  • Over the last 5 years, Serina Therapeutics' EBIT Margin had its largest YoY gain of 396279100bps in 2024, and its largest YoY loss of -432133300bps in 2024.
  • Serina Therapeutics' EBIT Margin (Quarter) stood at 6914.81% in 2021, then tumbled by -222bps to 22275.0% in 2022, then soared by 100bps to 7.81% in 2023, then soared by 507599bps to 39635.71% in 2024, then plummeted by -111bps to 4280.77% in 2025.
  • Its EBIT Margin was 4280.77% in Q2 2025, compared to 39635.71% in Q4 2024 and 37942.86% in Q3 2024.